Drug Profile
Cetrelimab - Janssen Research and Development
Alternative Names: JNJ 63723283; JNJ-3283Latest Information Update: 14 Apr 2024
Price :
$50
*
At a glance
- Originator Janssen Research & Development
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Bladder cancer
- Phase II/III Multiple myeloma
- Phase I/II Non-small cell lung cancer; Prostate cancer; Solid tumours; Urogenital cancer
- Phase I Hepatitis B
Most Recent Events
- 28 Mar 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (unspecified route) (NCT06311578)
- 13 Nov 2023 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease) in USA (unspecified route) (NCT06116786)
- 20 Oct 2023 Efficacy and adverse event data from the phase II SunRISe-1 trial in Bladder cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023) (NCT04640623)